Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst ...

Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.

The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...

Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...

Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Piper ...

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of ...

In a report released yesterday, Charles Duncan from Cantor Fitzgerald initiated coverage with a Buy rating on Alkermes (ALKS – Research ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%. Looking ahead, revenue ...

BofA analyst Jason Gerberry lowered the firm’s price target on Alkermes (ALKS) to $28 from $29 and keeps a Neutral rating on the shares. The company reported a relatively in-line Q3 and ...

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, ...

Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago. These figures are ...

Greetings and welcome to the Alkermes' Third Quarter 2024 Financial Results Conference Call. My name is Maria and I'll be your operator for today's call. All participant lines will be placed on ...